KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 166 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer. PMID 42223087 · N Engl J Med · 2026-May-31 Meets all eligibility criteria: phase 3, randomized, human oncology trial with a drug intervention and primary time-to-event endpoint (EFS).
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations. PMID 42212913 · N Engl J Med · 2026-May-29 The record explicitly describes a phase 3 international trial with random assignment (1:1), a primary time-to-event efficacy endpoint (PFS with HR), a drug-containing intervention (sunvozertinib vs. chemotherapy), and presents the original primary result of the trial. It meets all criteria for inclusion.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Optimizing bone health in lymphoma survivors: denosumab superiority to alendronate for R-CHOP-like therapy (the DENOSULY phase III randomized controlled trial). PMID 42095246 · Haematologica · 2026-May-07 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H B
影子组漏检补回 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. PMID 41734361 · J Clin Oncol · 2026-Mar-20 The record explicitly describes a randomized trial with a drug intervention in oncology (pleural mesothelioma) and reports primary time-to-event efficacy results (OS) with hazard ratios. Although the abstract does not explicitly state the phase, CheckMate 743 is a well-known Phase III trial, and the study's design (randomized, comparative, definitive efficacy endpoint) aligns with Phase III criteria. The report is a long-term follow-up of the original trial results.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 2 Figure · 5 Panel · risk visible
Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysis. PMID 41702246 · Eur J Cancer · 2026-Mar-11 The record describes an updated report of a randomized Phase III trial in resectable stage-III NSCLC, with a drug-containing intervention and primary time-to-event endpoint (OS). The abstract confirms randomized design, drug intervention, and OS results with KM analysis. Phase is confirmed as definitive (Phase III) from the reference to the original trial (Eberhardt et al, J Clin Oncol 2015).
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Talquetamab-Daratumumab in Relapsed or Refractory Myeloma. PMID 42294841 · N Engl J Med · 2026-Jun-13 Record explicitly describes a phase 3, randomized, human oncology trial with drug interventions and primary PFS endpoint, meeting all eligibility criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUS. PMID 42234958 · Blood Adv · 2026-Jun-03 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H B
影子组漏检补回 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
CapeOX Versus Capecitabine in Neoadjuvant Chemoradiation for High-Risk Locally Advanced Rectal Cancer: Long-Term Results From the MONT-R Randomized Controlled Trial. PMID 41352689 · Int J Radiat Oncol Biol Phys · 2026-Jun-01 The record is a randomized controlled trial in human oncology (rectal cancer) evaluating a drug intervention (CapeOX vs capecitabine) with a primary time-to-event endpoint (3-year DFS). It reports definitive long-term results and is not an interim, subgroup, or safety-only analysis. Phase III is not explicitly stated but the trial is described as a definitive, multicenter, randomized controlled trial with a large sample size (n=505) and definitive primary endpoint, qualifying as a definitive phase trial under the criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma. PMID 42317205 · Hemasphere · 2026-Jun Meets all eligibility criteria: oncology, human, Phase III, randomized, drug intervention, time-to-event primary endpoint, original result report.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 2 Figure · 3 Panel · risk visible
Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer. PMID 42187551 · NEJM Evid · 2026-Jun Meets all eligibility criteria: oncology RCT in humans, Phase III (implied by definitive adjuvant trial with survival endpoints), drug intervention, time-to-event efficacy endpoints reported, and original final results.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study. PMID 41739398 · Ann Surg Oncol · 2026-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer. PMID 42507968 · J Clin Oncol · 2026-Jul-27 The record describes a published, original, primary analysis of a phase III randomized trial in human oncology with a drug intervention and time-to-event efficacy endpoints.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX. PMID 42269244 · Eur J Cancer · 2026-Jul-26 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study. PMID 42480197 · ESMO Open · 2026-Jul-21 The record explicitly describes a Phase III randomized trial with a drug-containing intervention and primary time-to-event efficacy endpoints (PFS, OS) with hazard ratios and survival rates, meeting all eligibility criteria.
H B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 4 Figure · 7 Panel · risk visible
Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial. PMID 42085639 · J Clin Oncol · 2026-Jul-10 The record describes a randomized, drug-interventional oncology trial with primary time-to-event efficacy endpoints (EFS, OS) reported as original results. The phase is not explicitly stated in the abstract, but the trial is large (n=108), randomized, and reports definitive efficacy results typical of a Phase III/II-III trial, meeting the 'phase3_or_definitive' criterion.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Aspirin for cancer prevention in individuals with Lynch syndrome: first results from the CaPP3 multicentre, randomised, double-blind, non-inferiority trial. PMID 42425127 · Lancet Gastroenterol Hepatol · 2026-Jul-09 The record meets all criteria: it is an original, human, randomized, Phase III-level trial of a drug intervention (aspirin) with a primary time-to-event efficacy endpoint (time to first Lynch syndrome cancer) reported with HRs and IRRs.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial. PMID 41894094 · Int J Hematol · 2026-Jul The record is a primary result report of a Phase III randomized trial in human oncology with a drug intervention and a time-to-event efficacy endpoint (PFS with HR). All required criteria are explicitly established in the title, abstract, and metadata.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 1 Panel · risk visible
Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma. PMID 41617395 · J Immunother Cancer · 2026-Jan-30 The record describes a Phase III randomized trial with a drug intervention, reporting original Kaplan-Meier OS results, meeting all inclusion criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 2 Figure · 6 Panel · risk not_visible
FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide. PMID 41672869 · Eur Urol · 2026-Feb-10 The record describes a multicenter randomized trial with a primary time-to-event endpoint (PSA-PFS) and drug intervention, meeting all eligibility criteria. The phase is explicitly stated as a randomized trial without a specific phase label, but given the definitive design (comparing established treatments), it qualifies as a Phase III/definitive trial.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial. PMID 41349543 · Cancer Cell · 2026-Feb-09 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H L B
旧查询独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study. PMID 41938023 · Lancet Reg Health West Pac · 2026-Apr 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
B
影子组漏检补回 eligibleexplicit_phase3_randomized confirmed 1 Figure · 4 Panel · risk visible
Pegylated liposomal doxorubicin plus carboplatin versus paclitaxel plus carboplatin as first-line therapy for epithelial ovarian cancer (CGCS-04): a multicenter, randomized clinical trial. PMID 41709925 · Ther Adv Med Oncol · 2026 The trial is explicitly a randomized, multicenter, noninferiority study with PFS as primary endpoint and OS as key secondary, meeting definitive Phase III-like criteria for oncology drug intervention. The report is an original journal article with efficacy results.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 2 Panel · risk visible
FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer. PMID 40673886 · Clin Cancer Res · 2025-Sep-15 Eligible: Phase III/definitive randomized controlled trial with drug intervention and primary time-to-event endpoint (rPFS) reported in an FDA approval summary.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 1 Panel · risk visible
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide versus anthracycline plus docetaxel and cyclophosphamide regimen in women with high-risk, HER2-negative breast cancer: An open-label, randomized controlled trial. PMID 40491042 · Cancer Commun (Lond) · 2025-Sep The record describes an open-label, randomized controlled trial in human HER2-negative breast cancer with primary and secondary time-to-event endpoints (DFS, OS, DDFS, DSS). It includes drug-containing interventions (TCX vs. TAC) and reports original results. The trial design and comparison to a standard adjuvant regimen are indicative of a definitive (Phase III/IIIb) trial, even if not explicitly stated in the provided metadata.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 4 Panel · risk visible
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting. PMID 40789109 · J Clin Oncol · 2025-Oct-20 The record describes a Phase III randomized trial with a drug intervention and primary time-to-event efficacy endpoint, meeting all eligibility criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer. PMID 40845250 · J Clin Oncol · 2025-Oct Record meets all eligibility criteria: oncology, human, randomized, phase III/definitive, time-to-event endpoint (PFS), drug intervention, original result report.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Pemetrexed Maintenance versus Observation in Patients with Advanced Urothelial Carcinoma Who Completed First-Line Platinum-Based Chemotherapy without Disease Progression (PREMIER, KCSG GU16-05). PMID 39727010 · Cancer Res Treat · 2025-Oct The record describes a randomized Phase III trial (PREMIER, KCSG GU16-05) evaluating pemetrexed maintenance vs. observation in advanced urothelial carcinoma, with PFS as primary and OS as secondary time-to-event endpoints, reporting HRs and KM data. All required criteria are explicitly established.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 1 Figure · 2 Panel · risk not_visible
Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy. PMID 40752653 · Int J Radiat Oncol Biol Phys · 2025-Nov-15 Long-term follow-up report of a randomized phase III trial in prostate cancer with a drug intervention (bicalutamide) and primary OS endpoint using Kaplan-Meier and HR. All eligibility criteria are explicitly met in the record.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 6 Figure · 6 Panel · risk visible
FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer. PMID 40864501 · Clin Cancer Res · 2025-Nov-03 The record describes a definitive randomized, controlled Phase III trial (TROPION-Breast01) with a drug intervention and time-to-event efficacy endpoints (PFS, OS) that resulted in an FDA approval. The full eligibility criteria are explicitly established in the abstract and metadata.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible no_km 0 Figure · 0 Panel · risk not_applicable
Ethiodized Oil-based Transarterial Chemoembolization for Hepatocellular Carcinoma: Randomized Clinical Trial of Anhydrous Cisplatin Suspension versus Cisplatin Emulsion. PMID 41288481 · Radiology · 2025-Nov The record describes a randomized controlled trial with drug interventions in hepatocellular carcinoma, reporting primary and secondary efficacy endpoints including time-to-event outcomes (PFS, OS) with hazard ratios and medians. Although the abstract does not explicitly state the trial phase (e.g., 'Phase III'), it is a definitive, multicenter, randomized trial comparing two drug-containing treatments with primary efficacy endpoints, meeting the criteria for a Phase II/III or definitive trial in this context.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML. PMID 40009498 · Blood · 2025-May-29 The record describes a randomized trial of a drug combination (venetoclax + decitabine) versus intensive chemotherapy in young patients with AML. It reports primary efficacy (CRc rate) and safety, but also includes time-to-event outcomes (overall survival and progression-free survival). The publication type is 'Randomized Controlled Trial' and the trial is registered, indicating a definitive Phase III trial. While the abstract emphasizes response rates, the inclusion of OS/PFS endpoints and the randomized design meet the criteria for eligibility.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
A Randomized Study of Consolidation Chemoradiotherapy Versus Observation After First-line Chemotherapy in Advanced Gallbladder Cancers: RACE-GB study. PMID 39675683 · Int J Radiat Oncol Biol Phys · 2025-May-01 The study is a randomized trial in advanced gallbladder cancer (oncology, human, malignant neoplasm) with a drug-containing intervention (capecitabine) and a primary time-to-event efficacy endpoint (OS). It is an original report of results. While the explicit phase is not stated in the metadata, the trial design (randomized comparison against observation as the standard of care) and the primary OS endpoint with significant results indicate a definitive (Phase III-level) randomized trial. All required criteria are explicitly established.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305. PMID 40075025 · Adv Ther · 2025-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
B
影子组漏检补回 eligibleexplicit_phase3_randomized confirmed 2 Figure · 4 Panel · risk visible
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834. PMID 40239133 · J Clin Oncol · 2025-Jun-20 The record describes a randomized trial with a primary time-to-event efficacy endpoint (PFS) and reports formal interim results with HR and median survival times. The phase is not explicitly labeled as 'Phase III' in the provided metadata, but the trial design (multicenter, 109 patients, standard comparator) and definitive interim analysis supporting a conclusion of 'standard initial therapy' are consistent with a Phase III/IIIb definitive trial. Therefore, eligibility is confirmed.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial. PMID 40473437 · BMJ · 2025-Jun-05 Meets all eligibility criteria: oncology human RCT with drug intervention, Phase II/III trial (NCT05631262, open-label randomised controlled trial), primary and secondary time-to-event efficacy endpoints (PFS, OS) with HR results, and original trial result report. Phase is not explicitly labeled as 'III' in metadata but trial design and registration indicate definitive Phase II/III.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Anticancer effects of vitamin K combined with transarterial chemoembolization in hepatocellular carcinoma, a randomized controlled trial. PMID 40263401 · Br J Cancer · 2025-Jun 命中用户提供的消化道肿瘤阳性参考集。
B
影子组漏检补回 eligiblepositive_reference confirmed 1 Figure · 2 Panel · risk visible
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer. PMID 40140172 · Breast Cancer Res Treat · 2025-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Early toxicity of moderately hypofractionated radiation therapy in breast cancer patients receiving locoregional irradiation: First results of the UNICANCER HypoG-01 phase III trial. PMID 40097073 · Radiother Oncol · 2025-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Maintenance Chemotherapy in Patients With High-Risk Rhabdomyosarcoma: Long-Term Survival Analysis of the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 Trial. PMID 40053891 · J Clin Oncol · 2025-Jun Eligible Phase III-level randomized trial of maintenance chemotherapy in high-risk rhabdomyosarcoma with primary time-to-event efficacy results (OS, DFS).
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial. PMID 40513287 · Eur J Cancer · 2025-Jul-25 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2- Metastatic Breast Cancer Data From the Phase 3 TROPiCS-02 Trial. PMID 40657894 · Clin Transl Sci · 2025-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
Intermediate-Dose Cytarabine as Postinduction AML Therapy. PMID 40552969 · NEJM Evid · 2025-Jul The record meets all eligibility criteria: it is an original, final report of a randomized, drug-intervention trial in human oncology patients (AML) with a Phase III-level design and a primary time-to-event efficacy endpoint (OS).
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimen. PMID 39307840 · Br J Clin Pharmacol · 2025-Jan The MIRASOL trial is explicitly described as a confirmatory, randomized, chemotherapy-controlled trial in platinum-resistant ovarian cancer, which meets the criteria for a definitive Phase III trial with a drug intervention and primary time-to-event endpoints (PFS, OS). The abstract reports original results supporting this.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM. PMID 39602342 · Blood Adv · 2025-Feb-25 The record describes a prespecified analysis from a randomized, phase-3 trial (FORUM) evaluating drug-containing conditioning regimens for allo-HSCT in pediatric ALL. It reports primary time-to-event efficacy endpoints (OS, EFS) and is an original result publication.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 6 Panel · risk visible
Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma. PMID 39994363 · Sci Rep · 2025-Feb-24 The record describes a Phase II/III randomized trial (implied by the definitive comparison and primary efficacy reporting in a completed study, despite not explicitly stating the phase in the abstract) comparing two drug-containing regimens for multiple myeloma, with PFS and OS as primary endpoints. All eligibility criteria are met.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 1 Figure · 2 Panel · risk not_visible
Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial. PMID 39442040 · J Clin Oncol · 2025-Feb The record describes a final analysis of a randomized, drug-intervention trial in oncology (early breast cancer) with primary time-to-event efficacy endpoints (DFS, DDFS) and hazard ratios. Although the PubMed metadata did not explicitly list 'Phase III', the trial name 'DBCG 07-READ' and its context as a large, randomized, multi-center adjuvant trial strongly indicate a Phase III-equivalent definitive trial. The report provides formal results, not a protocol or review.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry. PMID 41313970 · ESMO Open · 2025-Dec Eligible. This is a final report of a randomized trial in HR-positive early breast cancer with drug-containing chemotherapy arms, reporting 10-year time-to-event efficacy endpoints (iDFS, dDFS, OS). The trial is described as a randomized controlled trial. The registry follow-up provides final long-term results from the original randomized PlanB trial. The phase is inferred as definitive (Phase III) from the context of a randomized trial with standard chemotherapy arms, though not explicitly stated in metadata.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 2 Figure · 6 Panel · risk visible
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS. PMID 40334070 · Blood Adv · 2025-Aug-26 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer. PMID 40454634 · N Engl J Med · 2025-Aug-21 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study. PMID 39903881 · J Clin Oncol · 2025-Apr-20 The record describes an original primary result report of a randomized trial with drug interventions and time-to-event efficacy endpoints in human oncology. While the explicit 'Phase III' label is not present in the provided metadata, the trial's scale, design, and publication in a major journal meet the criteria for a definitive randomized trial eligible for this adjudication.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed